Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity
Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors
Xenetic Biosciences Announces Full Year 2013 Financial Results and Business Update
Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis
Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors
Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA
Xenetic Biosciences Announces Ticker Symbol Change to XBIO
